Immunovant's IMVT-1402 hits primary endpoint in difficult-to-treat rheumatoid arthritis trial
The company reports ACR20 response of 92.5% versus 75.6% for placebo at Week 28, with FDA discussions planned for later this year to chart a registrational path.
SEC filing